Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial by unknown
ORIGINAL ARTICLE
Efficacy and safety of oral recombinant calcitonin tablets
in postmenopausal women with low bone mass and increased
fracture risk: a randomized, placebo-controlled trial
N. Binkley & H. Bone & J. P. Gilligan & D. S. Krause
Received: 12 June 2014 /Accepted: 25 June 2014 /Published online: 16 July 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract
Summary The effect of an investigational oral calcitonin tab-
let upon bone mineral density (BMD) of the spine was inves-
tigated in postmenopausal women with low bone mass and at
increased risk of fracture. Compared to placebo, calcitonin
tablets increased lumbar spine BMD. This agent may provide
an additional choice for patients.
Introduction An investigational oral salmon calcitonin prepa-
ration was previously shown to increase lumbar spine BMD in
postmenopausal women with osteoporosis. Our objective was
to evaluate the use of this agent in postmenopausal women
with low bone mass and at increased fracture risk but not
meeting BMD criteria for osteoporosis.
Methods Treatment-naïve women were randomized to re-
ceive oral recombinant salmon calcitonin tablets or placebo
once daily for 1 year. Dual-energy X-ray absorptiometry was
performed at baseline and at study weeks 28 and 54. CTx-1, a
bone resorption marker, was obtained at the same time points.
Subjects returned periodically for tolerability assessment and
adverse event (AE) recording.
Results One hundred twenty-nine women in the USA were
randomized, 86 to calcitonin and 43 to placebo. Calcitonin
recipients experienced a significant increase from baseline in
lumbar spine BMD; the difference compared with placebo
was significant. Dosing at bedtime or with dinner was equally
effective. CTx-1 was suppressed in calcitonin recipients but
not in placebo subjects. Gastrointestinal AEs were common,
but the overall safety profile was comparable between groups.
Conclusions Oral calcitonin may provide a useful therapeutic
alternative for some women with low bone mass.
Keywords Bonemineral density . Calcitonin . Oral .
Osteopenia . Osteoporosis
Introduction
Osteoporosis occurs most commonly in women, due in part to
lower peak bone mass and rapid perimenopausal bone loss
[1]. Osteoporosis-related fractures result in substantial mor-
bidity, health care cost, loss of independence, and increased
mortality [2]. The majority of these fractures occur in women
who do not have osteoporosis as defined by their bonemineral
density (BMD) [3]. As a result, much recent effort has focused
on improving identification of those who will fracture includ-
ing use of risk calculators such as the World Health
Organization’s FRAX® tool [4]. Indeed, it has recently been
suggested that osteoporosis be diagnosed in those at increased
fracture risk [5, 6].
In spite of these personal and societal costs, and in the face
of an aging population, use of medications to reduce fracture
risk has declined dramatically, even following hip fracture [7,
8]. This decline is certainly multifactorial but is likely due in
large part to concerns about side effects including rare com-
plications such as osteonecrosis of the jaw (ONJ) and atypical
femoral fractures (AFFs). As such, a clear need exists for
medications that safely reduce bone loss with advancing age.
The calcitonins are 32 amino acids, naturally occurring
calcium-regulating peptide hormones produced by the thyroid
glands in mammals and the ultimobranchial glands in birds
and fish [9]. Calcitonins have long been used as therapeutic
agents because of their antiresorptive properties, effected by
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intracellular second messengers following binding to specific
G protein-coupled receptors on osteoclasts, resulting in
nonapoptotic inhibition of osteoclastic activity [10].
Pharmaceutical preparations in Europe and the USA generally
employ synthetic salmon calcitonin, which is regarded as a
more potent antiresorptive than human calcitonin [11]. In the
USA, recombinant and synthetic salmon calcitonin nasal
sprays and synthetic injectable formulations are approved for
osteoporosis treatment in women who are at least 5 years
postmenopause and for whom other agents are contraindi-
cated or refused [12].
Nasal calcitonin is well tolerated but produces only modest
blood levels; an oral preparation might provide a desirable
alternative for some patients and might help to improve initial
acceptance of therapy and subsequent compliance. However,
oral delivery of peptide agents is challenging, principally due
to enzymatic digestion in the proximal gastrointestinal tract.
We have previously demonstrated that an investigational oral
recombinant salmon calcitonin preparation is bioavailable and
increases lumbar spine BMD to a greater degree than calcito-
nin nasal spray in postmenopausal women with established
osteoporosis [13]. Because bone resorption is greatest over-
night and the effect of calcitonin is transient, the investiga-
tional calcitonin preparation was administered in the evening
[14]. In the present study, we evaluated this preparation in
postmenopausal women with osteopenia and an elevated frac-
ture risk as calculated using the FRAX tool, who did not meet
a T-score definition of osteoporosis [15]. The entry criteria for
elevated risk in this study were designed to mirror the US
Preventative Services Task Force recommendations for iden-
tifying women with increased risk of osteoporosis [16]. We




Women ≥45 years of age and at least 5 years postmenopause
with BMD T-score<−1.0 but>−2.5 at the lumbar spine, total
hip, femoral neck, or trochanter were eligible for the study.
Eligible subjects had serum FSH≥0 mIU/mL, serum 25
hydroxyvitamin D ≥20 ng/mL, and body mass index (BMI)
≤35 kg/m2. Subjects were also required to have clinical risk
factors such that the 10-year risk of major osteoporotic frac-
ture as determined by the FRAX algorithm was at least as
great as a 65-year-old woman of the same race with a BMI of
25 kg/m2, and without additional risk factors. As an example,
for a 65-year-old (US) white woman with this BMI, the 10-
year risk levels of a major osteoporotic fracture or hip fracture
are 9.3 and 1.2 %, respectively. Major exclusion criteria were
history of osteoporotic fracture, T-score≤−2.5 at any of the
sites listed above, treatment with hormone replacement ther-
apy within 3 months of randomization, and prior use of
calcitonin, bisphosphonates, denosumab, fluoride, strontium,
or parathyroid hormone analogs.
Study design
Two screening visits occurred after written informed consent
was obtained. At the first screening visit (visit 0), the 10-year
risk of a major osteoporosis fracture or hip fracture was
assessed using the WHO FRAX tool (“FRAX1”, i.e., without
BMD data). At the next screening visit (visit 1), within 30
days of visit 0, a BMD determination of the anterior-posterior
lumbar spine, femoral neck, trochanter, and total hip was
performed via dual energy x-ray absorptiometry (DXA). In
addition, a baseline blood sample was drawn for determina-
tion of C-terminal telopeptide of type 1 collagen (CTx-1), a
biochemical marker of bone resorption.
At or following visit 2, which occurred within 30 days of
the first screening visit (visit 0), the FRAX risk was
recalculated including the femoral neck BMD value obtained
at visit 1 (“FRAX2”). If the subject met all study inclusion
criteria (either FRAX calculation could serve as the qualifying
criterion), she could be enrolled. Eligible subjects were then
given a 14-day supply of placebo study medication and
instructed to take this at either bedtime or dinner time for a
2-week single-blind (i.e., subject blinded) run-in phase.
Subjects were also provided 600 mg calcium citrate and
1,000 IU vitamin D supplements to take once daily with
breakfast throughout the study. The purposes of the run-in
phase were to determine tolerability of the excipients used in
the formulation of both the placebo and oral calcitonin and
also of the calcium citrate and vitamin D supplementation and
to confirm subject compliance.
At visit 3, 2 weeks after beginning the run-in period, each
subject’s eligibility for randomization to double-blind treat-
ment was determined based on all prior screening results,
tolerability of the blinded placebo study medication during
the run-in phase, and compliance with the assigned placebo
medication and supplement. If a subject was deemed ineligi-
ble due to lack of tolerability, refused to continue, or was not
compliant, any treatment-emergent adverse events (TEAEs)
were documented, and the subject was discontinued from the
study. Eligible, continuing subjects were randomized in a 2:1
ratio to receive identical appearing oral calcitonin or placebo
tablets. Initially, subjects were to take the assigned medication
at bedtime on an empty stomach. Following receipt of data
from a phase 1 study that suggested no food effect on the
pharmacodynamic response (i.e., suppression of serum CTx-1
levels) to the oral calcitonin preparation, the protocol was
modified during the study’s enrollment period so that newly
enrolling subjects were instructed to take oral calcitonin or
placebo with the evening meal.
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The study duration was 54 weeks, including the 2-week
run-in phase. BMD and CTx-1 were measured at the second
screening visit (visit 1), week 28 (visit 6), and week 54 (visit
8). Subjects experiencing a BMD loss of ≥7 % at any mea-
sured site at week 28 were to be discontinued from the study.
Treatments
Study volunteers were provided identical appearing tablets
containing either 0.2 mg (200 μg/1,200 IU) of recombinant
(Escherichia coli) salmon calcitonin or placebo. The formu-
lation of this product has previously been reported [13].
Briefly, each tablet core contains 0.2 mg of recombinant
salmon calcitonin and 500 mg of citric acid (CA). The tablet
cores have an acid-resistant enteric coat, which dissolves in
the basic environment of the proximal small bowel, releasing
the CA and calcitonin. The CA provides a lower pH acidic
microenvironment, inhibiting endogenous enzymes in the
proximal small bowel, which function optimally in a basic
medium. Oral calcitonin and placebo were supplied by the
sponsor. Calcium and vitamin D supplements were obtained
commercially by each clinic site.
Participants self-administered the assigned tablet daily with
a glass of water approximately 1 h before sleeping, until the
protocol amendment changed the time of study drug admin-
istration to be with the evening meal.
Bone density measurement
BMD was measured at the lumbar spine (L1–L4) and proxi-
mal femur (the neck, trochanter, and total hip) using replicate
DXA scans at screening, week 28 and the week 54 final visit.
BMD results were averaged if the two scans were within 5 %
of each other. If the results fell outside of this range, a third
scan was obtained, and the two scans closest to one another
were averaged. Each participant was scanned on the same
densitometer throughout the study. All DXA scans were
reviewed independently in blinded fashion by two expert
technicians at a central imaging facility (BioClinica, Inc.,
Newtown, PA) for technical adequacy of acquisition and then
analyzed in accordance with prespecified standard guidelines.
Bone biomarker
Fasting blood samples were obtained prior to 11AM at base-
line, week 28, and week 54 for determination of CTx-1, which
was measured by Pacific Biomarkers, Inc., Seattle, WA, using
a commercial assay (Elecsys®, Roche Diagnostics). The pre-
cision values and limit of quantitation obtained in validation
assays were consistent with the manufacturer’s data in the
product’s label.
Safety assessments
A complete physical examination was performed, and speci-
mens for safety laboratory analyses (clinical chemistry, hema-
tology, and urinalysis) were collected at screening (visit 0). A
symptom-directed exam and assessment of adverse events
were performed at each subsequent visit, and safety laboratory
studies were to be repeated at weeks 28 and 54 or the exit (last)
visit.
Statistical analysis
The primary objective was to compare the effects of oral
calcitonin to placebo with respect to the change from
baseline in lumbar spine BMD measurements over a 54-
week period (i.e., 52 weeks of treatment). The primary
efficacy variable was the percent change from baseline in
lumbar spine BMD values over 52 weeks. A modified
intent-to-treat (MITT) subject population was used for all
efficacy analyses. This population was defined as all
subjects who received treatment and had at least one
postbaseline BMD value. In subjects who completed
week 28 but did not complete the full 54-week period,
the data were imputed using the last observation carried
forward (LOCF) method. All statistical methods were
described in a statistical analysis plan completed prior to
any unblinding. To test robustness of the results for the
primary efficacy variable, which was based on the mixed
effect model repeated measure (MMRM) model with
LOCF, a sensitivity analysis was planned, using this
MMRM model without LOCF. Secondary efficacy vari-
ables included lumbar spine (LS) BMD, as assessed by
the percent change between baseline and week 28 and
BMD changes at the femoral neck, trochanter, and total
hip, as assessed by the percent change between baseline
and both weeks 28 and 54.
Safety and tolerability were assessed through the recording
of adverse events (AEs) throughout the study, as well as by
review of the safety laboratory determinations performed
periodically. The safety population was used for all safety
analyses, defined as all subjects who received one dose of
study drug after randomization, i.e., following the run-in
period.
The sample size was estimated assuming a treatment
group difference of 1.5 %, a standard deviation of 2.5 %,
two-sided significance level of 0.05, power equal to 80 %,
and a 2:1 randomization. Based on these assumptions, it
was determined that a total of 102 subjects would need to
be randomized, 68 to the oral calctionin group and 34 to
the placebo group. In order to obtain 102 women com-
pleting therapy, 120 eligible women meeting the inclusion
and exclusion criteria and providing informed consent
were to be randomized 2:1 (active/placebo).
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Results
Participant characteristics
The study was conducted at 11 sites in the USA. Two hundred
and eighty volunteers provided informed consent and were
screened for entry; of these, 144 were eligible and entered the
run-in phase, and 129were randomized to calcitonin or placebo.
Demographic characteristics of the safety population are
displayed in Table 1. Study participants were predominantly
white, normal to overweight, vitamin D replete, postmenopaus-
al women with a mean age of 67 years. FRAX scores were
slightly lower when calculated with inclusion of femoral neck
BMD (FRAX 2) compared to screening (FRAX 1, not shown).
T-scores were lowest at the femoral neck. There were no statis-
tically significant differences between treatment groups for any
baseline characteristic.
Participant disposition is presented in Fig. 1. Of 144 wom-
en entering the single-blind run-in phase, 129 were random-
ized. The most common reason for not continuing to random-
ization was not tolerating the placebo tablet or calcium/
vitamin D supplement (N=10, see “Safety and tolerability”
below). Other reasons for failure to proceed to randomization
(N=5) included poor compliance or the subsequent identifi-
cation of exclusion criteria (such as a prior history of fracture
or inability to obtain an adequate DXA scan). The 129 sub-
jects proceeding to randomization constitute the safety popu-
lation. The efficacy analysis was conducted in the MITT
population of 114 subjects, 78 in the calcitonin group and 36
in the placebo group. Ninety-nine women completed all study
visits. The proportion discontinuing was slightly higher in the
placebo group, although the proportion of subjects
discontinuing for tolerability reasons was similar between
groups (see “Safety and tolerability”). Additional reasons for
discontinuation included withdrawal at the subject’s request
(five placebo, six calcitonin), lost to follow-up (one each),
investigator decision, and BMD loss ≥7 %, one each in the
placebo arm.
Bone mineral density
Changes from baseline in BMD at the various anatomic sites
over the course of the study are displayed in Table 2; the
change in LS BMD over time is displayed in Fig. 2. Over 54
weeks, calcitonin recipients experienced a significant im-
provement from baseline in LS BMD(1.03 %, p<0.001),
while placebo recipients experienced a nonsignificant de-
crease in LS BMD from baseline. The difference between
groups, 1.14 %, was statistically significant (p=0.027). The
sensitivity analysis, performed without using the LOCF, also
Table 1 Baseline subject characteristics (mean±SD)
Baseline characteristics Safety population
Oral calcitonin Placebo Totala
(n=86) (n=43) (n=129)
Age (years) 67.5±6.9 66.6±5.2 67.2±6.4
Race (% white) 94.2 95.3 94.6
Height (cm) 161.2±6.5 161.0±7.0 161.1±6.6
BMI (kg/m2) 25.8±3.8 26.8±6.0 26.1±4.6
FRAX-2 (%, major)b 11.3±4.4 11.3±4.5 11.3±4.4







Femoral neck T-score −1.69±0.5 −1.73±0.3 −1.70±0.4
Total hip T-score −1.23±0.5 −1.20±0.5 −1.22±0.5
Trochanter T-score −0.95±0.7 −0.99±0.6 −0.98±0.6
a p>0.05 for all pairwise comparisons
b FRAX calculated using femoral neck BMD
Fig. 1 Participant disposition
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indicated a significant change from baseline LS BMD in the
calcitonin cohort (1.11 %, p<0.001) but not the placebo
cohort. The difference in change in LS BMD between groups
was also significant in this sensitivity analysis. Over 28
weeks, the mean percent LS BMD change from baseline in
the MITT oral calcitonin cohort was 0.96 %, p<0.001; the
placebo cohort experienced a nonsignificant LS BMD de-
crease from baseline. The difference, 0.95 %, approached
statistical significance ( p=0.069).
Among the calcitonin recipients, 50 and 36 individuals
were assigned to evening meal or bedtime administration,
respectively; the corresponding numbers were 25 and 18 in
placebo recipients. Among calcitonin recipients, the LS BMD
change did not differ according to the time of administration
(dinner 1.25 % vs bedtime 0.87 %, p=NS).
Total proximal femur BMD loss was reduced in the
oral calcitonin group at both weeks 28 (p=0.05) and 54
(p=0.048) relative to placebo recipients. The mean per-
cent changes from baseline in femoral neck and tro-
chanter BMD at weeks 28 and 54 were not significant
for either cohort nor were there significant differences
between the cohorts.
Serum CTx-1
CTx-1 values were significantly reduced from baseline in the
calcitonin cohort at weeks 28 and 54 (p<0.001 and 0.041,
respectively) (Table 2 and Fig. 3). The difference between
cohorts in CTx-1 values was significant at both time points
(p<0.001 and 0.034, respectively). Subjects in the placebo
cohort had a numerically higher mean CTx-1 value at both
time points; at week 54, this trended toward significance (p
value=0.058).
Safety and tolerability
During the run-in period, 10 women reported 21 AEs and
discontinued because of tolerability. The most common sys-
tem involved was gastrointestinal, with seven (4.9 % of all
patients entering the run-in) events leading to discontinuation.
None of these events was classified as severe or serious.
The AEs reported after randomization, i.e., TEAEs, are
displayed in Table 3. The proportion of women experiencing
any TEAE was comparable between the two groups, 81.4 %
Table 2 Bone mineral density
and CTx-1
Data presented as least square
mean (95 % confidence intervals)
p Values denote oral calcitonin
versus placebo
Bold values differ from baseline
(p<0.05) based on within group t
test comparison
Change from baseline Oral calcitonin Placebo p Value
N=78 N=36
Lumbar spine BMD, %
Week 28 0.96 (0.38,1.54) 0 (−0.84,0.85) 0.06
Week 54 1.03 (0.46,1.59) −0.12 (−0.94,0.71) 0.02
Femoral neck BMD, %
Week 28 0.14 (−0.70, 0.42) −0.56 (−1.38, 0.26) NS
Week 54 −0.26 (−0.90, 0.39) −0.30 (−1.25, 0.64) NS
Trochanter BMD, %
Week 28 0.09 (−0.50, 0.68) −0.67 (−1.52, 0.18) NS
Week 54 −0.10 (−0.75, 0.55) −1.07 (−2.02, −0.12) NS
Total hip, BMD, %
Week 28 −0.02 (−0.35, 0.31) −0.61 (−1.09, −0.12) 0.05
Week 54 −0.13 (−0.56, 0.30) −0.89 (−1.52, −0.27) 0.05
CTx-1, %
Week 28 −24.6 (−33.6, −15.56) 4.2 (−8.8, 17.14) <0.01
Week 54 −11.8 (−22.2, −1.43) 8.4 (−7.11, 23.85) 0.03
Fig. 2 Mean percent change in lumbar spine BMD over time Fig. 3 Mean percent change in CTx-1 over time
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in the placebo cohort and 79.1 % in the oral calcitonin group.
Severe TEAEs were less common in the placebo cohort
(one subject [constipation, 2.3 %] vs ten subjects [11.6 %],
respectively); however, no pattern was obvious in the severe
TEAEs of calcitonin recipients: upper abdominal pain, pyrex-
ia, acute hepatitis, sepsis, contusion, fall, laceration, lumbar
vertebral fracture, breast cancer, meningioma, and syncope.
No clinically meaningful differences in the frequency of mod-
erate TEAEs occurred between the placebo and oral calcitonin
cohorts (18 subjects [41.9 %] vs 34 subjects [39.5 %],
respectively).
Sixty-five subjects (50.4 %) experienced a TEAE that was
considered by the blinded investigator to be treatment-related.
The only treatment-related TEAE experienced by >10 % of
subjects in either cohort was upper abdominal pain in the
placebo cohort.
No deaths were reported during the study, and less than
10 % of subjects experienced a serious AE (SAE). Serious
TEAEs and TEAEs that led to discontinuation were report-
ed in both cohorts. Two subjects (4.7 %) in the placebo
cohort experienced two SAEs, and six subjects (7.0 %) in
the calcitonin cohort experienced nine SAEs. Neoplasm
(one subject had breast cancer in each cohort) and fracture
(one fracture each in tibia [screen failure], right hip [not
randomized], lumbar vertebrae [calcitonin cohort]) were
the only SAEs reported by >1 subject, and no SAEs were
considered related to the investigational product by the
blinded investigator(s).
Five subjects (11.6 %) in the placebo cohort experienced
15 events that led to discontinuation. Nine subjects (10.5%) in
the oral rsCT cohort had 14 events that led to discontinuation.
The TEAEs leading to discontinuation in the placebo cohort
Table 3 Summary of adverse
events: safety population Oral calcitonin Placebo
(N=86) (N=43)
Adverse event category n (%) No. of events n (%) No. of events
Any AE 68 (79.1) 211 35 (81.4) 102
Any SAE 6 (7.0) 9 2 (4.7) 2
Any treatment-related AE 40 (46.5) 79 25 (58.1) 65
Any AE with outcome of death 0 0 (0.0) 0 (0.0) 0
Any AE leading to discontinuation 9 (10.5) 14 5 (11.6) 15
Worst severity
Mild 24 (27.9) 16 (37.2)
Moderate 34 (39.5) 18 (41.9)
Severe 10 (11.6) 1 (2.3)
Table 4 Most commonly report-
ed adverse events: safety
population




Adverse event category n (%) No. of
events
n (%) No. of
events
At least one AE 68 (79.1) 211 35 (81.4) 102
Upper respiratory tract infection 8 (9.3) 10 7 (16.3) 8
Abdominal pain upper 6 (7.0) 9 6 (14.0) 9
Arthralgia 10 (11.6) 11 1 (2.3) 1
Nausea 8 (9.3) 11 3 (7.0) 5
Abdominal discomfort 9 (10.5) 11 1 (2.3) 1
Constipation 6 (7.0) 6 3 (7.0) 4
Abdominal pain 5 (5.8) 6 2 (4.7) 2
Diarrhea 5 (5.8) 5 2 (4.7) 5
Nasopharyngitis 4 (4.7) 4 3 (7.0) 3
Urinary tract infection 5 (5.8) 7 1 (2.3) 1
Pain in extremity 2 (2.3) 3 3 (7.0) 3
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were upper abdominal pain (three subjects [7 %]), and one
subject each with abdominal pain diarrhea, abdominal dis-
comfort, dry mouth, oral lichen planus, and decreased appe-
tite. The TEAEs leading to discontinuation in the oral calci-
tonin cohort were upper abdominal pain (three subjects
[3.5 %]) and abdominal pain (one subject [1.2 %]), and one
subject each with diarrhea, nausea, acute hepatitis sepsis, and
meningioma.
The most commonly reported AEs, i.e., those occurring in
≥5 % of either study arm, are shown in Table 4. The pattern of
AEs was similar across groups, with gastrointestinal AES
being reported most commonly; however, arthralgia was re-
ported more often in calcitonin recipients.
Discussion
In this phase 2 study, oral calcitonin increased LS BMD, re-
duced total proximal femur BMD loss, and reduced serumCTx-
1 in women with low bone mass and increased risk of fracture.
These results are similar to those observed in an earlier study
using this formulation of oral calcitonin compared to placebo
and nasal spray calcitonin in womenwith osteoporosis by BMD
[13]. The populations enrolled in these two studies were demo-
graphically similar, although the women in the present study
had higher baseline BMD based upon the study design.
Oral calcitonin was generally well tolerated. The safety
findings did not materially differ by treatment assignment,
and few women in either group experienced serious AEs.
Gastrointestinal AEs were common in both groups but were
typically mild and resolved upon discontinuation.
As calcitonin is a less potent antiresorptive than
bisphosphonates or the RANK-L inhibitor denosumab, it is not
surprising that the LS BMD improvement among oral calcitonin
recipients is modest compared to those agents. However, it is
likely that the antiresorptive potency of those agents accounts for
some of the AE association with these medications, e.g., ONJ
and AFF. To our knowledge, the complications associated with
profound suppression of bone remodeling such as ONJ and AFF
have never been reported with calcitonin.
Osteoporosis treatment is declining, even following hip
fracture [7, 8]. The reasons behind this are doubtlessly multi-
factorial; however, concerns about long-term safety are likely
in part responsible for this decline. Indeed, some physicians
and patients are reluctant to initiate bisphosphonate therapy in
view of concerns about AFF, even though the overall
risk/benefit profile is favorable. Based on concern about rare
side effects, a drug holiday has been recommended after 3–5
years of bisphosphonate use for low-risk patients, even though
there is a lack of prospective clinical evidence supporting this
recommendation, and the optimal duration of both holiday
and long-term use is unknown [15, 17, 18]. In this context,
less potent antiresorptive agents such as calcitonin may be
more acceptable to some patients and physicians.
However, concerns regarding AEs with calcitonin have
also been raised. Recently, the US prescribing information
for injectable and nasal calcitonins was revised to reflect a
“possible association between malignancy and calcitonin-
salmon use,” although no (black) boxed warning was added,
and no mechanism has been identified [12]. This putative
association has been discussed at great length and is of uncer-
tain biological plausibility. For example, individuals with
medullary thyroid carcinoma, which may elaborate high
levels of human calcitonin, are not at increased risk of second
malignancy [19]. Moreover, no signal of carcinogenicity was
apparent in formal preclinical animal carcinogenicity testing
or in spontaneous AEs reported to the FDA [20]. We have
previously reported that the frequency of AEs consistent with
malignancy was not elevated in this trial, in the larger phase 3
trial, or when data for these two trials were integrated [21, 22].
Limitations of our study include an absence of fracture data;
the revised prescribing information for nasal spray calcitonin
notes “fracture reduction efficacy has not been demonstrated.”
Calcitonin did not improve hip BMD, but our study may have
been underpowered to detect such differences.
In summary, based on modest effects on bone resorption
and BMD, oral calcitonin may provide a useful alternative for
postmenopausal women for whom other therapeutic classes
are contraindicated or poorly tolerated.
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